Bladder cancer is the sixth most common cancer in the U.S. People diagnosed with bladder cancer in northwestern Pennsylvania ...
Intravesical chemotherapy involves a healthcare professional injecting chemotherapy medication directly into the bladder to treat cancerous tumors. “Intravesical” means “within the bladder.” ...
Clinical utility of urine tumor DNA in bladder cancer patients. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after ...
A review of studies including 20,000 patients with NMIBC highlights the need for individualized NMIBC management that balances oncologic control with QoL and patient-reported outcomes. Frequent ...
The most common form of bladder cancer is transitional cell carcinoma (TCC). Non-muscle-invasive TCC is classified as stage Ta when the tumour is confined to the urothelium with no spread into the ...
INVEST: A phase Ib window of opportunity study of atezolizumab administered either intravesically or direct tumour injection in patients with bladder cancer prior to radical cystectomy. This is an ...
Transitional cell carcinoma is the most common form of bladder cancer. Non-muscle-invasive transitional cell carcinoma is classified as stage Ta when the tumour is confined to the uroepithelium with ...
UGN-102 could become the first FDA-approved treatment for low-grade intermediate-risk non-muscle-invasive bladder cancer, with a PDUFA goal date of June 13, 2025. The phase 3 ENVISION trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results